Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial
Author(s):
Fontein, D.B.Y.; Houtsma, D.; Nortier, J.W.R.; Baak-Pablo, R.F.; Kranenbarg, E.M.K.; Straaten, T.R.J.H.M. van der; Putter, H.; Seynaeve, C.; Gelderblom, H.; Velde, C.J.H. van de (0000-0003-0104-1800); Guchelaar, H.J. (0000-0002-7085-1383)
Published
2014
Publication type
Article / Letter to editor
Breast cancerCyp19ExemestaneAromatase inhibitorsAdverse eventsPharmacogeneticsPharmacotherapy
Date issued
2014-04-30
Language
English
Is part of
Breast Cancer Research and Treatment (2014), Vol. 144, no. 3, p. 599-606
